News & Views
Partnership highlights growth in Autoantibody Profiling Sector
Mar 01 2022
Global immunodiagnostics group Oncimmune has signed a partnership with Synexa Life Sciences BV, a provider of biomarker analytical and advisory services in translational and clinical research, that will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.
Both companies will utilise their expertise to improve patient diagnostics and therapeutics and over the next 18 months Synexa plans to sign multiple new contracts with its partners for autoantibody profiling, that will broaden the business development efforts of Oncimmune’s technology platform.
This new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.
Dr Adam M Hill, CEO of Oncimmune said: “We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform.
The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”
More information online
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia